Treatment is an BTK inhibitor and has demonstrated a sound safety and tolerability profile

Phase 1/2 research shows that treatment could be very effective against Fabry disease

Next phase of Newel Health’s digital therapeutics solution for Parkinson’s disease gains vital grant

New top line data has emerged from the company’s phase 1b study evaluating potential for treating sepsis

Research will analyse how Huawei’s wearable technology detects atrial fibrillation in post-stroke patients

Updated Date: Tue, 14 Feb 2023 00:00:00 EST

Updated Date: Tue, 14 Feb 2023 00:00:00 EST

Boost for effected patients as HEMGENIX receives green light from European Commission

Final draft guidance from NICE ensures people at highest risk will have access to COVID-19 therapies

Updated Date: Mon, 13 Feb 2023 00:00:00 EST